CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, today announced the publication of new animal data for its Vascugel™ product under investigation to aid in healing, function, and remodeling of traumatized veins and arteries.
The study suggested that Vascugel™, a biologically-active matrix of endothelial cells that is placed directly on damaged blood vessels to stimulate natural repair and regeneration, was instrumental in significantly increasing the diameter of injured vasculature, and reduced vascular narrowing, in tests utilizing a porcine model of arteriovenous (AV) grafts.
